Financial support: We would like to thank the support of donations from our grateful patients at MedStar Washington Hospital Center. This work was also supported by NIH NCI grant R01 CA116477. I for lungs, liver, heart, kidneys and bone marrow were obtained for each study (rhTSH and THW). A total of 22 lesions in three patients were identified. The contours were drawn on each PET image of each study. Time-integrated activity coefficients were calculated and used as input in OLINDA/EXM sphere dose calculator to obtain the absorbed dose to tumors.
the D per unit administered activity of 131 I was higher in the THW study compared to the rhTSH study. The ratio of the average tumor D after stimulation by THW compared to stimulation by rhTSH injections was 3.9, 27 and 1.4, for Pt1, Pt2 and Pt3, respectively. The ratio of mean tumor to bone marrow absorbed dose per unit administered activity of 131 I, after THW and rhTSH was: 232 and 62 (Pt1); 12 and 0.78 (Pt2); 22 and 11 (Pt3), respectively.
Conclusion:
The results suggest a high patient variability in the overall absorbed dose to the normal organs per MBq of 131 I administered, between the two TSH stimulation methods. The tumor to dose-limiting-organ (bone marrow) absorbed dose ratio, i.e. the therapeutic index was higher in the THW-aided compared to rhTSH-aided administrations. Additional comparison for tumor and normal organ absorbed dose in patients prepared using both methods is needed before definitive conclusions may be drawn regarding rhTSH versus THW patient preparation methods (1) (2) (3) (4) , and further study is warranted. For the absorbed dose to non-tumor tissues, more reports have been published. These publications typically evaluated whole body and/or bone marrow dosimetry using 131 I or 123 I, used dosimetry calculation methods that were not specifically developed for radiopharmaceutical therapy, which are not as quantitative as 124 I-PET/CT based methods and were not necessarily performed in patients with metastatic disease, and/or did not compare THW versus rhTSH injections in the same patient (3) (4) (5) (6) (7) (8) . The objective of this study was three-fold: to calculate the absorbed dose to bone marrow and multiple other critical organs (e.g. lung, liver, heart, and kidneys) by using 124 I-PET/CT and dosimetry software that specifically accounts for patient anatomy and activity distribution (e.g. 3D-RD) in patients with metastatic DTC, to calculate the absorbed dose to tumors and the tumor to dose-limiting organ absorbed dose ratio for both studies (rhTSH and THW), and to compare the absorbed doses to those critical organs and tumors after preparation with THW versus rhTSH with the patient being his/her own control. I-PET/CT scans were again collected as described above.
Patients Demographics
The four patients are notated as: Pt1, Pt2, Pt3 and Pt4. Demographics and relevant clinical parameters are tabulated in Table 1 . The 124 I administered activity for each study and the administered activity prior to 131 I therapy for each patient are given in Table 2 .
by on October 21, 2017. For personal use only. jnm.snmjournals.org Downloaded from
Activity Quantification
The sensitivity of the Philips Gemini time-of-flight camera was measured by scanning an 124 I standard of a known 124 I activity and was determined to be 296 cps/MBq. The 124 I sample was placed in a vial and the activity was measured using a dose calibrator. The vial was positioned at the center of the field of view of the PET/CT camera and imaged using a single bed scan.
Overview of Dose Calculation Approach
Normal tissue absorbed doses were obtained using the previously developed software package 3D-RD. Given the overall comparative nature of the study, many of the key features of 3D-RD, namely radiobiological modeling and voxelized dosimetry, were not utilized; nevertheless the use of personal anatomy of each patient justifies using such personalized software. Likewise the tumor absorbed dose calculations were performed using standard methods rather than a voxelized approach and radiobiological modeling.
Dosimetry Calculations for the Normal Organs
The activity for 
Image Registration and Volume of Interest Determination
First, all the serial PET/CT images for both THW and rhTSH injection studies were registered across time to the first time-point CT image of the study prepared with rhTSH injections, using a non-rigid or deformable registration algorithm with the imaging software Velocity To separate the dose to the lungs from the absorbed dose to tumors, the tumor volumes were excluded from the lungs' VOIs. The heart wall could not be distinguished on CT and therefore the dose calculation represents dose averaged over heart-wall and contents. A streak artifact in the CT image of patient Pt4 affected the attenuation correction of the serial PET images for this patient, and specifically the bed position covering part of the liver and the kidneys. For this reason, these two organs were not included in the dose calculations for Pt4.
Image Processing and Monte-Carlo Simulation
The registered CT and PET images were used in 3D-RD to generate patient-specific anatomy and patient-and study-specific activity images. The attenuation image derived from CT was used to define the corresponding spatial tissue density (density map) and composition Radiation Dose radionuclide data and decay scheme database (15) .
VOI Based Analysis
The energy deposition from Monte Carlo simulation was scored for each time-point in each VOI and divided by the mass of the VOI, obtained from CT, in order to calculate the dose rate.
The dose-rate values for almost all normal organ VOIs exhibited a single-phase clearance over the measured time-points and were fit using a mono-exponential function. The one exception was for the Pt2 THW lung VOI, which study exhibited a period of uptake and was fit using a hybrid (trapezoidal-exponential) fit consisting of linear fits between the first two time-points and an exponential tail obtained by fitting to the final three time-points. The period of uptake observed in the lungs is consistent with the presence of diffuse lung metastases. The integration of the curve was calculated in each case to obtain the absorbed dose.
Bone Marrow Dosimetry
VOIs covering the thoracic and lumbar vertebrae (between T9-L4, depending on the patient) were manually drawn on the CT images for bone marrow dosimetry. The volumes of bone marrow VOIs were 120, 134, 94 and 53 ml for each patient, respectively. No corrections were made for partial volume effects. The bone marrow activity was obtained from the serial PET images and marrow dose calculations were performed by following the 3D-imaging based method described in Woliner-van der Weg et al. (16), with the exception that CT drawn VOIs instead of functional image based VOIs were used here. No further assumptions or corrections were made in the bone marrow dose calculations.
Dosimetry Calculations for Tumors
Detailed tumor dosimetry calculations were performed according to the Medical Internal Radiation Dose formalism given in Pamphlet 21 (17) . A total of 22 tumors were identified: 9, 2 and 11 tumors in three patients. Initially, tumor contours were drawn on the CT image using the To compare aggregate tumor kinetics relative to bone marrow kinetics for each patient, we summed the activity in all tumors at each time-point and divided by the total tumor mass. This was used to plot an aggregate tumor activity versus time curve that may be compared with the bone marrow time-activity curve under each preparation method. I administration and the clearance half-lives for five organs and each study. The rhTSH clearance half-life was longer than that of THW for bone marrow of Pt1 and Pt4, and all studied organs for Pt3. The rhTSH clearance half-life was faster than that of THW for the rest of the studied organs. The following organs exhibited a higher initial uptake in the rhTSH study compared to THW: the heart and bone marrow for Pt1, all the studied organs for Pt3, and the lungs and heart for Pt4. The initial uptake for the rest of the organs was lower in the rhTSH study compared to the THW study.
RESULTS
The difference in the obtained time-integrated activity coefficients between THW and rhTSH divided by the time-integrated activity coefficient of the THW study is shown in Figure 4 .
The time-integrated activity coefficient for the kidneys and bone marrow of Pt1, all studied organs of Pt3 and lungs and heart of Pt4 was higher in the rhTSH study compared to THW. The timeintegrated activity coefficient was lower in the rhTSH compared to THW for the rest of the organs.
The normal organ absorbed dose results are summarized in Table 3 . The absorbed dose per unit administered activity is lower in the THW study compared to the rhTSH for kidneys and bone marrow of Pt1 and heart of Pt4, and higher for the rest of the organs for Pt1 and Pt4. For Pt2, the absorbed dose per unit administered activity is higher in the THW study compared to rhTSH for all studied organs. For Pt3, the absorbed dose per unit administered activity is lower in the THW study compared to rhTSH for all studied organs. The observations on the difference in timeintegrated activity coefficients between rhTSH and THW translate to the difference in the absorbed dose results between rhTSH and THW for Pt1, Pt2 and Pt3.
The THW to rhTSH absorbed dose per unit administered activity of 131 I ratio, averaged over five organs (lungs, heart, liver, kidneys and bone marrow) for Pt1, Pt2 and Pt3, was 1.5, 2.5 and 0.64, respectively. The THW to rhTSH absorbed dose ratio averaged over three organs (lungs, heart and bone marrow) was 1. Figure 5 . a-c, respectively). For Pt1, Pt2 and Pt3 initial activity uptake is higher in the tumors compared to bone marrow. Although it is possible that the first study affected the subsequent one, we believe this is unlikely for the following reasons. The normal organs that were studied are not known to typically have sodium iodine-symporters, so the possibility of "stunning" such as to normal thyroid tissue is unlikely to be present in these normal non-thyroid tissues. Although stunning from 124 I is possible in metastatic lesions, given the low level of 124 I activity, stunning in metastatic lesions is unlikely.
DISCUSSION
In the unlikely scenario of stunning of the metastatic lesions from 124 I administration we would expect this to reduce the uptake in the metastatic lesions, thereby reducing any production of radiolabeled T3 and T4 with 124 I, and thus enhancing clearance from the whole body, not delaying it. A potential fourth limitation of this study is that the time interval between the two different preparations was approximately five to eight weeks. It is possible that during this time interval the patient's situation changed. For example, the patient's metastases could have progressed. This cannot be excluded but growth of metastases is unlikely to have affected organ clearance over the 5 to 8 week time-period. Repeat thyroglobulin levels were not available and would be less reliable because thyroglobulins are not necessarily consistent between stimulation from rhTSH injections and THW. In regard to a change in iodine intake, spot urine iodine levels were performed, but they are less than ideal and may be inadequate and problematic for several reasons. As reported by Sohn et al. (19) and Kim et al. (20) , spot urine iodine levels are inferior not only to the reference standard of 24-hour urine iodine measurements but also to spot urine iodine/creatinine ratios. Also, patients who were prepared with rhTSH injections continue to receive thyroid hormone, and despite a patient being compliant with his/her low iodine diet, the thyroid hormone has iodine content.
Patients are also variable in their compliance with a low iodine diet. One patient had a very high urine iodine level, only one measurement during THW, and no measurements at all. Thus, because of these factors, a limitation of the study is the inability to strictly control and/or adequately measure urine iodine intake. Finally, an additional limitation is possibly the low prescribed activity that was administered.
From a dosimetric standpoint, the study would have benefitted from an uncertainty analysis. However, this is a substantially complex subject and an area of active research where very little in the way of definitive data or methodologies exist. Several generalities concerning uncertainties can intuitively be given: many of the systematic uncertainties will cancel out for direct comparison, the uncertainties are certainly greater for tumors than for normal organs, the combination of uncertainty and variability reinforces the notion that within this data set neither preparation approach gives higher or lower uptake or absorbed dose for the normal organs, and that THW has a qualitatively higher therapeutic index is unlikely to be affected by any uncertainties.
Unlike the previous studies, our study evaluated multiple critical organs in patients prepared with both THW and rhTSH injections that heretofore were not all evaluated with 124 I and 3D-RD software. Multiple previous reports demonstrated reduced absorbed dose to the blood (e.g. bone marrow) in patients prepared with rhTSH injections (3) (4) (5) (6) (7) (8) . The reduced absorbed dose to the organs is attributed to the more rapid clearance of radioiodine when the patient is euthyroid versus hypothyroid (21). In our study, which consisted of four patients with metastatic disease, we observed a high patient variability in the uptake and absorbed dose results to normal organs overall between rhTSH and THW.
The absorbed dose to blood was found to be lower after stimulation with rhTSH than that in patients after THW in previous studies (22, (7) the absorbed dose to the bone marrow is calculated based on collected blood time-activity data and following the blood dosimetry method described by Sgouros et al. (24, 25) . Woliner-van der Weg et. al. (16) compared the blood-based, planar image-based and 3D image-based red bone marrow dosimetry (using the 3D-RD software) approaches, in terms of the absorbed dose to the red bone marrow and the predictability of red bone marrow toxicity. In this study the authors showed that the 3D-RD based red bone marrow dosimetry is a more sensitive predictor for the selection of patients showing any grade of red bone marrow toxicity than blood-based and planar image-based red bone marrow doses (16) . Nevertheless, there is room for improvement in the calculation of the blood dose: a microscale model with marrow cavities, adipose cells and trabecular bone integrated into the macro-scale imaging would certainly be beneficial. The interior vertebral VOI consists of a mixture of trabecular bone and marrow space contents, i.e. red and yellow marrow, blood vessels, extracellular fluid and vasculature. In this study it was assumed that the activity concentration within the VOI is uniform and no further corrections were applied to account for differences in activity concentration or density within the VOI. Previous studies by Schwartz et al. (26) 
CONCLUSION
This study calculated the absorbed doses to normal organs including not only bone marrow, but also lung, heart, liver, and kidney as well as tumors, per MBq of 131 I administered in patients with metastatic differentiated thyroid cancer.
The dosimetry calculations for the normal organs were performed based on the 124 I-PET/CT imaging and using the patient-specific 3D-RD software. In addition, the patient was his own control in the comparisons between rhTSH and THW. The results suggest a high patient variability in the overall absorbed dose to the normal organs per MBq of 131 I administered between the two TSH stimulation methods. The tumor absorbed dose per unit administered activity was higher in the THW study than in the rhTSH study for the majority of the tumors (~86%). The therapeutic index or the tumor to dose-limiting organ (bone marrow) absorbed dose ratio was higher when the patient was prepared using THW compared to when rhTSH was used.
Although participation in this study or similar studies is demanding for patient volunteers, further recruitment of volunteers, in particular female volunteers for this or similar studies is warranted. In addition, studies are warranted to not only prospectively evaluate patient outcomes after 131 I therapy in patients prepared with rhTSH versus THW, but also to evaluate the potential benefit of THW combined with rhTSH.
In regard to the present use of rhTSH preparation in patients with metastatic DTC, we submit that until further data are available, the use of rhTSH preparation in patients who cannot tolerate THW is a reasonable alternative, and in those patients who are able to tolerate THW, we recommend that the patient be explained the potential benefits and risks of each preparation so that each patient can make an informed decision regarding the approach taken.
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